Abstract. The receptor for nerve growth factor (NGF) comprises a 75-kDa (NGFR p75 ) and a tyrosine kinase A (TrkA) subunit. In view of conflicting opinions on the identity of glial targets of NGF in human central nervous system (CNS), we examined the cellular distribution of both NGF receptor subunits in normal CNS and in chronic multiple sclerosis (MS) lesions. For this, we compared the pattern of recognition of 2 monoclonal antibodies (mAbs) and a polyclonal antiserum to NGFR p75 . Only the 2 mAbs specifically recognized NGFR p75 , while the polyclonal antiserum showed widespread reactivity. In normal CNS and silent MS lesions, immunohistochemistry with anti-NGFR p75 mAbs and for TrkA revealed perivascular cell reactivity. At the edge of chronic active MS lesions, selective NGFR p75 staining was prominent on reactive astrocytes, while throughout the lesion, NGFR p75 was expressed on microglia/macrophages. The vast majority of mature or precursor oligodendrocytes did not express NGFR p75 . Both NGF receptors were co-expressed on a subset of inflammatory cells. Immunoreactivity for NGFR p75 on glial and immune cells did not correlate with the distribution of apoptotic figures, as detected by TUNEL. Thus, expression of NGF receptors in active MS lesions suggests a role for NGF in regulating the autoimmune response at both immune and glial cell levels.
INTRODUCTION
Nerve growth factor (NGF) is a survival/differentiation factor for neuronal and glial cells as well as for a subset of immune system elements. The receptor for this neurotrophin is composed of a low-affinity subunit of 75 kDa (NGFR p75 ) and a high-affinity tyrosine kinase type A (TrkA) (1) (2) (3) . The trophic influence of NGF depends on the presence of both receptors; TrkA was initially considered to be the biologically active molecule, the effect of which was potentiated by the low-affinity subunit (3) . However, subsequent studies demonstrated that NGFR p75 is also able to deliver Trk-independent signals (1, 2) . In this regard, in vitro investigations have demonstrated that the selective recruitment of NGFR p75 may induce either cell death (4-7), or anti-apoptotic effects through the activation of the transcription factor, NFB (8, 9) .
In recent years, compelling evidence from experimental and clinical studies has underscored an important role for NGF in central nervous system (CNS) autoimmune diseases (10) . Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are diseases associated with inflammatory infiltration of CNS white matter and consequent autoimmune destruction of myelin and of the myelin-forming cell, the oligodendrocyte (11). Up-regulation of NGFR p75 and/or NGF has been found in situ both in MS and in EAE (12) (13) (14) (15) . In addition, NGF treatment has been shown to exert protective effects in primate EAE (15) .
In order to understand better the molecular mechanisms mediating the NGF response in CNS autoimmune conditions, a fundamental issue is the identification of glial cell targets of NGF and their differential pattern of NGFR p75 and TrkA expression. In fact, receptor profile is known to influence the response to NGF and is therefore crucial in the analysis of the pathogenesis of autoimmune demyelinating diseases (2, 3, 10) . However, studies on the expression on glial cells of NGFR p75 and TrkA have provided conflicting results. Most information on NGF receptors on glial cells has come from studies in vitro, where oligodendrocytes display a TrkA-negative/ NGFR p75 -positive phenotype (4, 5, 9) , while expression of these molecules on microglia and astrocytes depends upon culture conditions (16) . Regarding the presence of NGF receptors in vivo, Frisen et al (17) reported that both receptors were not present on glial cells in the normal CNS, while other investigators described NGFR p75 reactivity on microglia (18) . In the course of CNS autoimmune diseases, NGFR p75 has been reported on oligodendrocytes (18, 19) , on their precursors (20) , and on astrocytes (15) .
In view of such discrepancies on the presence of NGFR p75 in normal CNS white matter and in chronic MS lesions, we decided to investigate its expression using different antibodies, some of which have been used in previous studies. We first compared by immunohistochemistry and Western blotting the specificity and pattern of recognition of 2 monoclonal antibodies (mAbs) and 1 polyclonal antiserum to NGFR p75 ; we found that only the mAbs specifically recognized the NGFR p75 , while the polyclonal antiserum showed widespread reactivity. In chronic active MS lesions, selective expression of NGFR p75 was observed on reactive astrocytes at the lesion edge and on microglia/macrophages throughout lesions. Interestingly, both NGFR p75 and TrkA were present on a subset of inflammatory cells and no association between presence of NGFR p75 and DNA fragmentation was observed, either on glial or inflammatory cells.
MATERIALS AND METHODS

Tissue Samples
Postmortem (between 4 and 15 h) CNS tissue was studied from 15 subjects (mean age 46 yr), with a clinical diagnosis of chronic progressive MS. A total of 22 blocks containing lesions and normal appearing white matter were examined. Histopathologically, 5 cases displayed a predominance of chronic active lesions with hypercellular margins, ongoing demyelination with macrophage and lymphocytic infiltration, and a hypocellular demyelinated center displaying fibrous astrogliosis and oligodendrocyte depletion. In the remaining 10 cases the majority of lesions were defined as chronic silent based on the absence of inflammation and the presence of gliotic, demyelinated centers. Brain tissue from 5 subjects (mean age 62.3 yr), with other neurological diseases (OND), was available for control purposes (1 case each of Alzheimer disease, amyotrophic lateral sclerosis, and olivopontocerebellar atrophy and 2 cases of stroke). Normal CNS tissue with no evident lesions came from 5 subjects (mean age 62 yr), succumbing to non-neurologic conditions. Sections of sural nerve biopsies from 2 patients with chronic inflammatory demyelinating polyradiculoneuritis were used as positive controls for NGFR p75 reactivity. All tissues were snap-frozen and stored at Ϫ80ЊC until use. A fragment of sciatic nerve isolated from limb amputation was homogenized and used as positive control for Western blotting experiments. All tissues were obtained under a protocol approved by the Institutional Review Board (IRB) for human subject research.
Immunohistochemistry
Immunofluorescence was performed on frozen sections according to a previously described procedure (21) . Briefly, sections were fixed in acetone, blocked with normal serum, and incubated overnight with primary antibodies at 4ЊC. The primary antibodies and their cellular targets were as follows: anti-NGFR p75 mAbs clone 8211 (Chemicon, Temecula, CA; 1:100) (22) and clone ME20.4 (Sigma, St. Louis, MO; 1:100); rabbit antiserum against the cytoplasmic domain of NGFR p75 (Promega, Madison, WI; 1:100); anti-TrkA antiserum (sc-763; Santa Cruz Biotechnology; Santa Cruz, CA; 1:50, respectively); antisera to myelin basic protein (MBP), GFAP, CD68, and CD3 for the identification of oligodendrocytes, astrocytes, microglia, and T lymphocytes, respectively (all from Dakopatts, Glostrup, Denmark; 1:200, 1:400, 1:100 and 1:50); anti-HLA-DR LN3 mAb for microglia/macrophages (Biotest, Dreieich, Germany; 1:5); and anti-NG2 antiserum (Chemicon; 1:100) for oligodendrocyte precursors. Anti-NGFR p75 antibodies were visualized with appropriate biotinylated Ig followed by streptavidin-Texas Red (Vector Laboratories, Burlingame, CA), while for phenotypic markers, fluorescein-conjugated Ig were employed either for single and double staining. Double staining with anti-NGFR p75 mAbs and the microglial markers, CD68 or HLA-DR, was performed by using fluorescein-conjugated KP1 or CR3/ 43 mAbs (Dako, 1:10), respectively. After washing, slides were mounted and viewed under a Zeiss MC80 fluorescence microscope. Negative controls included the use of non-immune serum or isotype-specific, irrelevant antibody; for TrkA, pre-absorption with the generating peptide (Santa Cruz Biotechnology) abolished the signal.
Western Blotting and Immunoprecipitation
Western blotting and immunoprecipitation analyses were performed according to previously described procedures (21) . Homogenized samples from normal human brain and sciatic nerve were dissolved in lysis buffer (DTT 0.5%, Nonidet P-40 1%, EDTA 10 mM in Tris-buffered saline) with protease inhibitor Complete TM (Roche, Mannheim, Germany). Samples were clarified by centrifugation and supernatants used for Western blotting and immunoprecipitation. Protein concentration was determined by bicincholinic acid and bovine serum albumin as standard. Prior to immunoprecipitation, samples were precleared with protein A-agarose (Roche) for 3 h and subsequently incubated with the anti-NGFR p75 mAbs or antiserum. Immunocomplexes were retrieved with protein A-agarose beads after overnight incubation. Total cell lysates, immunoprecipitates, and the respective supernatants were boiled for 5 min in Laemmli buffer; proteins were separated in 8% SDS-PAGE and transferred to PVDF membranes Immobilon P (Millipore, Bedford, MA). After saturation, membranes were probed with antiTrkA anti-serum and monoclonal or polyclonal antibodies to NGFR p75 . Immunoprecipitates obtained with the mAb were probed with the anti-NGFR p75 antiserum and, vice versa, immunoprecipitates with the antiserum were visualized with anti-NGFR p75 mAb. Immunoreactive bands were detected with the appropriate Ig conjugated to peroxidase and visualized on autoradiographic film by enhanced chemiluminescence (Amersham, Buckinghamshire, England).
Apoptosis Assay
Apoptotic figures in MS sections were assessed by the terminal deoxynucleotidyl transferase-mediated fluorescein-conjugated dUTP nick end-labeling (TUNEL) technique (Roche), as previously described (23, 24) . After fixation and permeabilization, reaction mixture was added and the sections incubated at 37ЊC. In negative controls the enzyme was omitted. The phenotype of TUNEL-positive cells was assessed by double immunostaining, as described above.
RESULTS
In normal CNS, immunohistochemistry with anti-NGFR p75 antiserum revealed constitutive expression on microglia, oligodendrocytes, axons, and some perivascular cells (Fig. 1A) . On the other hand, immunoreactivity with anti-TrkA antiserum and anti-NGFR p75 mAbs was observed on cells around meningeal and parenchymal vessels, but not on glial elements (Fig. 1B, C) ; positive cells had an elongated morphology, were GFAP-negative and corresponded to the leptomeningeal cells described by Frisen et al (17) . High levels of reactivity for NGFR p75 was detected on Schwann cells in nerve biopsy sections from chronic polyradiculoneuritis, while staining for TrkA was present on perineurial structures (data not shown), as previously reported (25) . The different patterns of NGFR p75 reactivity observed on CNS glial cells using the mAbs and the antiserum prompted us to investigate their fine specificity by Western blotting and immunoprecipitation techniques. By Western blotting, mAbs 8211 and ME20.4 yielded a single immunoreactive band of 75 kDa in PNS homogenate (Fig. 1D, lane 3) , and bands migrating at 50-35 and 15 kDa in the CNS homogenate (Fig. 1D, lane 4) , the latter likely representing truncated and/or deglycosylated forms. With the anti-NGFR p75 antiserum, broad reactivity with numerous bands was visible both in PNS and CNS homogenates (Fig. 1D, lanes 1 and 2, respectively) , a stronger reactivity at 75 kDa being apparent only in the PNS. With regard to TrkA, the expression of this NGF high-affinity receptor was confirmed by Western blotting in the CNS (Fig. 1E) , where we found immunoreactive bands at approximately 140 and 110 kDa, reflecting the presence of the full-length and truncated forms of the receptor, respectively; peptide preabsorption abolished the staining of these bands (data not shown). We then performed immunoprecipitation with anti-NGFR p75 polyclonal antiserum and mAb 8211 to further analyze their specificity. Immunoprecipitation with mAb 8211 yielded a 75-kDa band both in PNS and CNS homogenates, albeit with different intensities (Fig.  1F, lanes 3 and 4) . When immunoprecipitation was performed with anti-NGFR p75 antiserum, no detectable levels of NGFR p75 were visible in PNS and CNS samples (Fig. 1F, lanes 1 and 2) ; instead, a 75-kDa band was present in the supernates (data not shown). Thus, of the antibodies investigated, only the mAbs specifically recognized NGFR p75 , while wider reactivity was obtained with the antiserum. For this reason, only the mAbs 8211 and ME20.4 were employed in subsequent analyses of NGFR p75 expression in MS lesions. In OND cases and in chronic silent MS lesions, immunostaining for NGFR p75 and TrkA was similar to that observed in normal CNS; in particular, neither mature glial cells (Fig. 1G-L) nor NG2-positive precursors (Fig.  1M, N) , displayed NGFR p75 . In contrast to non-inflammatory conditions, high levels of NGFR p75 expression were detected within, but not outside chronic active MS lesions and the pattern of reactivity was similar using mAbs 8211 or ME20.4. Immunostaining for NGFR p75 was observed on distinct glial cell types depending on the area and degree of inflammatory activity in the plaque. At the edge of all chronic active MS lesions examined, the majority of cells reactive for NGFR p75 -positive were GFAP-positive astrocytes ( Figs. 2A-C) ; proceeding deeper into the lesion, the proportion of NGFR p75 -positive astrocytes gradually decreased. In addition, immunostaining for NGFR p75 was also observed on different glial elements throughout the lesion area. Based on cell shape and double staining with phenotypic markers, these cells were identified as microglia/macrophages. In fact, immunoreactivity for NGFR p75 was detected on many ramified HLA-DR-positive or CD68-positive microglia in the plaque center (Fig. 2D-F) ; NGFR p75 was also observed on some foamy macrophages, particularly around inflammatory infiltrates. In general, a positive correlation was observed between expression of NGFR p75 on microglia/macrophages and degree of inflammation. Examination of sections double stained with MBP or NG2 antisera and anti-NGFR p75 mAbs revealed that the majority of oligodendrocytes (Fig. 2G-I ) and their precursors (Fig. 2M-O) showed no reactivity for NGFR p75 ; only scattered MBP-positive ( Fig. 2J-L ) and NG2-positive cells located at the plaque edge were found to express NGFR p75 . Noteworthy was that TrkA was never observed on glial cells (Fig. 3D) . With regard to the expression of NGF receptors on inflammatory cells, we found that within the same lesion, some perivascular cuffs showed co-expression of NGFR p75 and TrkA on the majority of inflammatory cells (Fig. 3A, B) , while other infiltrates displayed no reactivity for both NGF receptors (Fig. 3C, D) .
Since selective expression of NGFR p75 (i.e. in the absence of TrkA) has been shown to trigger oligodendroglial cell death in vitro (4, 5, 7), we assessed whether the presence of NGFR p75 correlated with apoptosis by combining TUNEL and immunostaining for NGFR p75 . As previously reported by our group and others (20, 23, 24) , TUNEL-reactive profiles were confined to inflammatory elements and scattered microglial cells. We found no correlation between expression of NGFR p75 and TUNEL reactivity both in glial and inflammatory cell. In fact, glial cells undergoing apoptosis showed no expression of NGFR p75 (Fig. 2P, Q) and, within perivascular infiltrates, TUNEL-positive images were also detectable on inflammatory cells not expressing NGF receptors (data not shown).
DISCUSSION
The aim of this study was to evaluate the expression and cellular distribution of NGFR p75 and TrkA in normal human CNS and in chronic MS lesions, since conflicting results have been reported regarding expression of NGFR p75 on human glial cells (15) (16) (17) (18) (19) (20) . To investigate whether this discrepancy was related to technical differences, we assessed the pattern of recognition of a battery of anti-NGFR p75 antibodies, some of which were used in the above studies. Although all 3 antibodies employed recognized a 75-kDa-immunoreactive band by immunoblotting in PNS homogenates, only NGFR p75 mAbs 8211 and ME20.4 selectively reacted with their antigen, while the polyclonal antibody showed a broader reactivity with numerous bands immunostained in PNS and CNS samples. In CNS homogenates, mAb 8211 showed prominent bands at 50-35 and 15 kDa, probably representing truncated and/or deglycosylated forms. After immunoprecipitation of PNS and CNS proteins, selective recognition of NGFR p75 was accomplished by mAb 8211; in contrast, the polyclonal antiserum failed to immunoprecipitate NGFR p75 , which was detectable in the supernates instead.
The differing degrees of reactivity of these anti-NGFR p75 antibodies may help to explain the conflicting results on the distribution of NGFR p75 in normal CNS (17, 18) . In line with this, the distinct immunohistochemical patterns observed with anti-NGFR p75 polyclonal antiserum and mAbs reflected the different degree of specificity evidenced by Western blotting and immunoprecipitation. In fact, diffuse glial cell reactivity has been reported in normal CNS using the polyclonal antiserum (18) , while only leptomeningeal cells were stained by anti-NGFR p75 mAb (17) . The same technical limitations apply to MS where the presence of NGFR p75 , explored exclusively with anti-NGFR p75 polyclonal antiserum, has been reported on oligodendrocytes (18) or on their precursors (20) , within and around chronic MS lesions. The present immunohistochemical study for TrkA and NGFR p75 with the mAbs 8211 and ME20.4 showed no expression of either NGF receptor on glial cells in non-inflammatory conditions (i.e. normal CNS, OND, and chronic silent MS lesions), and in white matter adjacent to chronic active MS lesions. On the other hand, glial and inflammatory cells within chronic active MS lesions were found to display one or both receptors. Double staining with glial cell markers revealed NGFR p75 , but not TrkA, to be on reactive astrocytes at the lesion edge and on microglia/macrophages throughout the plaque. At variance with previous observations (18, 20) , we found that only scattered MBP-positive and NG2-positive cells displayed NGFR p75 , the majority of oligodendrocytes and their precursors being NGFR p75 -negative. In addition to glial cells, reactivity for both NGF receptors was seen on some inflammatory infiltrates, but not on others. On the whole, our results strongly suggest that the discrepancy between observations on NGFR p75 expression (15, 17, 18, 20) is mainly related to the different antibodies employed and, perhaps, to a different sampling or preparation of tissues. In fact, our study focused on frozen sections of chronic MS lesions and does not exclude the possibility that in more acute lesions or in tissue otherwise prepared, NGF receptors may be differently expressed on glial cells. We also investigated whether NGFR p75 expression on glial elements in MS lesions was associated with programmed cell death. In this regard, we confirmed previous observations that TUNEL-reactive elements displayed no reactivity for NGFR p75 (20) , thus ruling out a major role for NGF in vivo in the induction of glial cell death in chronic MS. As an alternative to a cytotoxic effect, one may hypothesize that NGF triggers activation of the transcription factor NFB with potential anti-apoptotic effects on NGFR p75 glial cells in MS lesions. In keeping with this, we and others have previously shown that NFB nuclear translocation occurred in microglia/ macrophages at the edge of chronic active MS lesions (26, 27) . Regarding astrocytes, activation of NGFRs by NGF resulted in morphologic changes upon these glial cells in vitro (28), whereas we are unaware of any literature showing astrocyte death by this neurotrophin.
With regard to possible mechanisms responsible for NGFR p75 up-regulation on glial cells in MS lesions, although the observed correlation with the degree of inflammation may herald a role for inflammatory mediators, their effect on NGFR p75 expression remains to be clarified. On the other hand, several lines of evidence suggest that autocrine/paracrine mechanisms may be involved in NGFR p75 up-regulation. In support of this, increased levels of NGF have been detected in MS and EAE (12, 14) , and astrocytes and T lymphocytes in vitro are capable of producing NGF (29, 30) , which in turn is known to up-regulate NGFR p75 on glial cells (31) . Taken in concert, the present findings show that NGF receptors are up-regulated on both glial and inflammatory cells in chronic MS lesions, but only during active inflammation, and that their expression is not associated with the induction of apoptosis. Whether NGF displays a down-regulatory effect on the immune response within the MS lesion, as shown in primate EAE (15) , remains a possibility. In this context, ongoing studies on glial cell cultures to investigate the modulation of cytokine profile exerted by NGF will contribute to the understanding of the proposed neuroprotective role of this neurotrophin in human autoimmune diseases. 
